SRR8518179
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.640
- MYC_TARGETS_V1+0.620
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.470
- OXIDATIVE_PHOSPHORYLATION+0.430
- MTORC1_SIGNALING+0.420
- GLYCOLYSIS+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.310
- DNA_REPAIR+0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
Top 10 suppressed
- TGF_BETA_SIGNALING-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- UV_RESPONSE_DN-0.330
- COAGULATION-0.320
- APICAL_JUNCTION-0.310
- ALLOGRAFT_REJECTION-0.270
- INFLAMMATORY_RESPONSE-0.270
- MYOGENESIS-0.270
- KRAS_SIGNALING_UP-0.260
- ANGIOGENESIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518230 | — | E | 0.898 |
| 2 | SRR8518170 | — | E | 0.885 |
| 3 | SRR8518376 | — | E | 0.868 |
| 4 | TCGA-CV-6003-01A-11R-1686-07 | — | — | 0.868 |
| 5 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.864 |
| 6 | TCGA-NC-A5HN-01A-11R-A26W-07 | — | cohortSQ2 | 0.861 |
| 7 | SRR1313151 | — | E | 0.860 |
| 8 | TCGA-A8-A07R-01A-21R-A034-07 | — | E | 0.858 |
| 9 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.857 |
| 10 | SRR8613729 | — | E | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.640 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.620 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |